MedTrace Logo

Sitagliptin Dose Comparison Study in Patients With Type 2 Diabetes (MK-0431-077)(COMPLETED)

NCT00541229 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2017-05-12

Study results available
· View outcomes & findings →

Summary

A study to assess the safety and efficacy of sitagliptin 100mg compared to sitagliptin 200mg in patients with type 2 diabetes.

Conditions

Interventions

DRUG

sitagliptin phosphate

sitagliptin 100 mg tablets q.d. (once daily) for 7 days.

DRUG

sitagliptin phosphate

sitagliptin 200 mg tablets q.d. (once daily) for 7 days.

DRUG

Comparator: Placebo

sitagliptin 100 mg \& 200 mg matching Placebo tablets q.d. (once daily) for 7 days.

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-24
Primary Completion
2008-06-17
Completion
2008-07-01

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00541229 on ClinicalTrials.gov